SAMSUNG BIOLOGICS CO.,LTD. [Amended] Single Sales/Supply Contract

View original on DART ↗0 votes · 0 comments

AI summary · Not investment advice

Samsung Biologics corrected the contract value of its contract manufacturing deal with a US pharmaceutical company to KRW 62.8 billion, or 8.95% of recent revenue.

Contract amount

KRW 62.8 billion

Key facts

Contract details: Pharmaceutical contract manufacturing agreement
Recent revenue: KRW 701.6 billion
% of revenue: 8.95%
Counterparty: A pharmaceutical company based in the United States
Contract period: 2020-10-28 to 2030-12-31
Contract date: Nov 3, 2020
Payment terms: No down payment or advance paymentNo down payment or advance payment
Disclosure deferral: Counterparty details withheld

Commentary

AI commentary · Not investment advice

What happened

Samsung Biologics disclosed a contract manufacturing agreement for pharmaceuticals with a U.S.-based drugmaker, and the filing corrects the contract amount to KRW 62.8 billion. The contract was signed on 2020.11.03 and runs from 2020-10-28 to 2030-12-31. The counterparty's name has been withheld from disclosure.

In the company's terms

Relative to the company, the contract amount equals 8.95% of its most recent revenue of KRW 701.6 billion. Against market capitalization, it is 0.1%. The company has made 6 disclosures of this type over the past year, with earlier ones dated 2026.10.02, 2026.09.10 and 2026.03.13.

What changes for shareholders

For shareholders, the filing states that the payment terms include no down payment or advance payment. The filing was received on 2026.11.02.

Earlier Single Sales/Supply Contract filings from this company

Filings of the same type
Filed	Counterparty	Contract amount	% of revenue
26.10.022026.10.02	A European pharmaceutical company	KRW 93.5 billion	2.05%

Show Korean comments

Comments

No comments yet

Comments from shareholders will appear here.

Get the next disclosure as an app alert

Get app alerts for new disclosures and stake changes on your watchlist